Meridian Bioscience (VIVO) Receives FDA Emergency Use Authorization for Revogene SARS-CoV-2 Molecular Assay

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. NVDA
6. IBM
7. PRIM
8. SPY
9. ACN
10. BLZE

Go back to Meridian Bioscience (VIVO) Receives FDA Emergency Use Authorization for Revogene SARS-CoV-2 Molecular Assay

Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay

November 10, 2021 8:55 AM EST

CINCINNATI, Nov. 10, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that their Revogene® SARS-CoV-2 assay was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).  Meridian expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021.

... More